الفهرس 
HEPATITIS C VIRUSOnly 14 pages are availabe for public view
 |  | from | 136 |  |  |
| | | from | 136 | | |
Abstract
Background & Aims: Single nucleotide polymorphisms (SNPs) in IL-10
gene promoter positions –1082 (rs1800896), 819 (rs3021097), and –592
(rs1800872) and IL28B gene (rs12979860) in adults were shown to be
associated with HCV clearance, In this study we aim to detect this
association and the relation of these SNPs to treatment response prediction
in Egyptian pediatric subjects with genotype 4 who received treatment with
pegylated interferon (PegIFN) plus Ribavarin (responders and nonresponders).
Patients and Methods: A RFLP-PCR and Real time PCR techniques were
used to genotype 54 pediatric patients with chronic hepatitis C (CHC) for
IL-10 SNPs and IL-28B SNP respectively. Group 1 of 34 patients received
combined therapy (PegIFN) and (RBV) for 24 weeks subdivided according
to their response to treatment into responders and non-responders, and group
2 of 20 healthy subjects (control).
Results: A significant difference (p<0.005) was observed in IL-28B
rs12979860 genotype frequencies between responders and non-responders to
interferon therapy, In responders CC genotype had greater frequency than
CT and TT genotypes (60%, 30%, 10%) respectively with C allele in its wild
genotype more likely to respond to treatment than in its mutant types. IL-10
_819 showed significant difference in its genotype frequencies between
responders and non-responders to therapy, where TT genotype had greater
frequency in responders that CT and CC (55%, 20%, 25%) respectively were
the subjects with T allele (CT/TT) showed higher rates of response than
those with no T allele (CC), its protective effect in both its recessive and
dominant forms.
Conclusion: SNP located 3 kb upstream of IL28B gene at (rs12979860) CC
genotype as well as the IL-10 gene SNP at _819 TT genotype are
significantly associated with response to PegIFN and RBV for pediatric
patients with CHC infection genotype 4. These polymorphisms explain
much of the difference in response between different genotypes and different
alleles and can be used for predicting response to treatment before patient is
prescribed to the expensive PegIFN-RBV therapy.
Key words: Interleukin 28-B, Interleukin 10, Hepatitis C virus